TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or “the Company”)
Issue of Equity
Bioventix plc
(“Bioventix” or the “Company”)
Unaudited Interim Results for the six months ended 31 December 2018
Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim financial results for the six-month period ended 31 December 2018.
To download this report as a PDF file click here.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
|
|
||
Bioventix plc
(“Bioventix” or “the Company”)
Issue of Equity
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has applied for 1,000 ordinary shares of 5 pence each (the “Option Shares”) to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the Option Shares on 4 February 2019.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
TR-1: Notification of major interest in shares.
To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or the “Company”)
Result of AGM
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.